The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
about
Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuitsClozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.DREADDs for Neuroscientists.DREADDS: Use and application in behavioral neuroscienceOptogenetic and chemogenetic strategies for sustained inhibition of pain.Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsResolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer DrugsGi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory NeuronsPET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation.Silencing Neurons: Tools, Applications, and Experimental Constraints.Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates.DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue.Activation of the Medial Prefrontal Cortex Reverses Cognitive and Respiratory Symptoms in a Mouse Model of Rett SyndromeThe use of chemogenetics in behavioural neuroscience: Receptor variants, targeting approaches, and caveats.Optogenetics and pharmacogenetics: principles and applications.New tools for understanding coping and resilience.Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.Applications of optogenetic and chemogenetic methods to seizure circuits: Where to go next?Chemogenetic Tools for Causal Cellular and Neuronal Biology.Dose-dependent reduction in cocaine-induced locomotion by Clozapine-N-Oxide in rats with a history of cocaine self-administration.Contemporary strategies for dissecting the neuronal basis of neurodevelopmental disorders.Inhibitory Gi/O-coupled receptors in somatosensory neurons: Potential therapeutic targets for novel analgesics.The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.Behavioral Effects of Acute Systemic Low-Dose Clozapine in Wild-Type Rats: Implications for the Use of DREADDs in Behavioral Neuroscience
P2860
Q28071885-2E7F4506-26EA-43B8-9373-14A345969051Q30370324-ACA612DD-8DC4-4E93-9955-113611A71D58Q36595793-C894F01F-60FC-46FF-B0D1-441E06171590Q36689339-4876D976-E698-416E-AA5C-26B2E2DD0496Q37147972-E7A7FF0E-9753-47FB-94A7-7F53A8FF3F05Q37183072-3C0EB614-45BC-47E8-B69F-D473D38A6A8AQ37235970-520A80A0-79AE-4D7B-9B35-D25C9846A629Q37372025-0B877D3D-2961-4E87-A69E-A127078CBDA0Q37493708-2747C964-65D3-46D2-B3A6-617B7DFC6E79Q38643921-00725B81-56A6-490B-8AF0-91CE9C351F92Q39151291-656B6742-92F0-4654-86F2-1C4A6E97F2CDQ45856308-43A8343F-808B-49A0-864E-03F4BDC9D351Q47524534-E34A794A-F8E4-4B48-B639-65E2C0890999Q47553027-3210F5CC-165F-4C97-B018-384CB2258B3CQ47971550-A1291F46-D23A-445F-8162-D0A26995F647Q48090828-3B846AA9-E94E-4517-8B0E-45C6A7A0B691Q48096641-8894A452-AD1D-40CB-9978-CF244A629D8CQ48268811-71930398-F8A9-4225-8116-6D22FE4D2D2AQ49917397-D0438A07-7F34-4403-B4D4-5E9C7E6526EEQ51735802-2A2ED5BF-DE64-477C-8FE3-49B85D43F482Q52351832-F4A61A28-84BB-40FB-9A02-6C331B121BD7Q52630403-7B6BE2A2-0B7B-4B29-A748-F7A88885BBB9Q52678173-F43B073F-8BCC-4530-BA4C-B30C1EAB48B6Q57169426-3CBD8BEB-F155-447D-ADB9-F55731C00194
P2860
The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The first structure-activity r ...... y activated by designer drugs.
@ast
The first structure-activity r ...... y activated by designer drugs.
@en
type
label
The first structure-activity r ...... y activated by designer drugs.
@ast
The first structure-activity r ...... y activated by designer drugs.
@en
prefLabel
The first structure-activity r ...... y activated by designer drugs.
@ast
The first structure-activity r ...... y activated by designer drugs.
@en
P2093
P2860
P356
P1476
The first structure-activity r ...... y activated by designer drugs.
@en
P2093
Bryan L Roth
Hyunah Choo
Orrin Stone
Xiaobao Yang
P2860
P304
P356
10.1021/CN500325V
P577
2015-01-27T00:00:00Z